Actinium Pharmaceuticals Inc. announced the presentation of new preclinical data for ATNM-400, its Actinium-225 based antibody radioconjugate, at the 2025 San Antonio Breast Cancer Symposium (SABCS). The data demonstrated robust anti-tumor activity and a favorable tolerability profile across various preclinical breast cancer models, including hormone receptor-positive, triple-negative, and tamoxifen- and trastuzumab-resistant tumors. ATNM-400 targets a validated cancer antigen overexpressed in breast cancer and other solid tumors such as prostate cancer and non-small cell lung cancer. The company indicated plans to advance the development of ATNM-400 toward clinical readiness. The results were presented at the 2025 SABCS.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY45419) on December 12, 2025, and is solely responsible for the information contained therein.